Bruker Daltonics Announces New 12 Tesla Ultra-High Field FTMS Magnet.Business/Technology Editors & Health/Medical Writers BIOWIRE2K ORLANDO, Fla.--(BW HealthWire)--June 3, 2002 Bruker Daltonics Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BDAL BDAL Battle Doll Angelic Layer (game) ) today announced the introduction of the first ultrahigh-field 12 Tesla (T) actively-shielded magnet for its APEX(R) IV Fourier Transform Mass Spectrometry (FTMS See Fusion FTMS. ) product line at the American Society for Mass Spectrometry The American Society for Mass Spectrometry is a professional association based in the United States that supports the scientific field of mass spectrometry. As of 2007, the society had approximately 7000 members primarily from the US, but also from around the world. (ASMS ASMS American Society for Mass Spectrometry ASMS Association of Salaried Medical Specialists ASMS Advanced Satellite Mobile Systems ASMS Alabama School of Mathematics and Science ASMS American Society for Mohs Surgery ASMS Arkansas School for Math and Science ) conference. It is expected that this cutting-edge magnet technology will be particularly important for proteomics. Bruker Daltonics has consistently been the pioneer in the development of innovative magnet technologies for FTMS, and its new 12T magnet is yet another milestone, as it represents the highest field commercially available. Bruker Daltonics has traditionally offered 4.7T, 7.0T, and 9.4 T magnets for FTMS. This latest 12T magnet redefines the term ultrahigh field in FTMS. The increase in field strength will further enhance key performance advantages of FTMS, including dramatic improvements in resolving power, sensitivity, mass range, and mass accuracy for life-science applications, particularly in proteomics. The new 12T superconducting magnet is actively shielded for straight-forward placement into standard biology and pharmaceutical laboratories. ABOUT BRUKER DALTONICS Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information about Bruker Daltonics, please visit www.bdal.com CAUTIONARY STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to technological approaches, product development, manufacturing, market acceptance, cost and pricing of Bruker Daltonics' products, dependence on collaborative partners, suppliers, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. and other risk factors discussed from time to time in Bruker Daltonics' reports or filings with the Securities and Exchange Commission. Bruker Daltonics expressly disclaims any obligation to update the information contained herein. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion